Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04883593 · ClinicalTrials.gov registry record · Early Phase 1
A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.
A Early Phase 1 study of Tinea Pedis, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT04883593: Completed Early Phase 1 study of Tinea Pedis, sponsored by Sun Pharmaceutical Industries.
NCT04883593 is a Early Phase 1 study of Tinea Pedis that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 160 participants, below the 309-participant average among 9 other Tinea Pedis trials with a reported enrollment target (48% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04883593, a Early Phase 1 study of Tinea Pedis, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate and compare the safety and efficacy of TA103 in the treatment of tinea pedis.
Primary Outcome
To evaluate safety and efficacy of TA103
Conditions Studied
Interventions
- DRUG Placebo Control
- DRUG TA103
Study Locations (1)
North Carolina
- Catawba Research, LLC - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2020-09-03 |
| Est. Completion | 2021-02-20 |
| Phase | Early Phase 1 |
What the finished NCT04883593 record still lists
NCT04883593 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 309-participant average among 9 other Tinea Pedis trials with a reported enrollment target (48% lower).
The record links to 1 condition, with Tinea Pedis appearing as the primary indexed condition, and to 2 interventions - of which Placebo Control is the first listed.
NCT04883593 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT04883593 about?
NCT04883593 is a clinical study titled "A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.". To evaluate and compare the safety and efficacy of TA103 in the treatment of tinea pedis.
What is the current status of trial NCT04883593?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 160 participants. The study started on 2020-09-03. Estimated completion is 2021-02-20.
What conditions does trial NCT04883593 study?
This clinical trial studies the following conditions: Tinea Pedis.
What interventions are being tested in trial NCT04883593?
The interventions under investigation include: Placebo Control (DRUG), TA103 (DRUG).
Who is sponsoring clinical trial NCT04883593?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04883593 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tinea Pedis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04883593's enrollment target sits among peer trials
160 5th of 9 higher than 5 of 9 other Tinea Pedis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tinea Pedis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Topical Tolnaftate Stick for Tinea Pedis: An Open-Label Interventional Study
RECRUITING · Phase 2
-
Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis
COMPLETED · Phase 1
-
A Study of Econazole Foam 1% in Athlete's Foot
COMPLETED · Phase 2
-
Spread of Dermatophytes Among Families
COMPLETED
-
BE Study of Naftifine HCL
COMPLETED · Phase 3
-
Three-Arm Trial of Novel Treatment for Tinea Pedis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI